SMITH & NEPHEW Iodosorb Powder, Cadexomer Powder with Iodine, 3g

Iodosorb powder is a sterile formulation of acute cadexomer iodine. When applied to the wound, it cleans it by absorbing fluids, removing pus and debris and forming a moist gel over the wound surface. As Iodosorb swells in situ the active iodine is released, killing resident micro-organisms in the wound site and changing colour.

It reduces bacteria, absorbs exudate, pus and debris,  facilitates desloughing and maintains a moist wound environment to promote healing of chronic ulcers and wounds such as venous stasis ulcers, pressure sores, diabetic foot ulcers, and infected traumatic and surgical wounds.

Each gram of cadexomer iodine can absorb up to 6ml of fluid. When Iodosorb Powder needs changing, it changes colour for easy identification. The powder forms a non-adhesive moist gel over the wound that can be easily removed without damaging the fragile new tissue underneath.

Benefits

• Clinically proven to treat infection
• Effective antimicrobial and deslougher
• High absorbency
• Wide range of high level clinical support
• Versatile range
• Changes colour as iodine is released
• Encourages wound healing
• Helps to eliminate odour

Directions

• Thoroughly clean the wound and surrounding area with a gentle stream of sterile water or saline. Remove excess fluid, leaving wound surface slightly moist.
• Apply powder to the wound surface to form a layer 3mm deep and cover with a dry dressing or gauze.
• Cover with an appropriate secondary dressing e.g. Melolin or Allevyn.
• To avoid the risk of cross-contamination, it is recommended that the use of a single sachet of Iodosorb Powder be confined to one patient.

Cautions

• As Iodosorb Powder contains 0.9% w/w Iodine it should not be used in patients with known or suspected Iodine sensitivity.
• Iodosorb Powder is contraindicated in Hashimoto's thyroiditis and in cases of nodular goitre.
• Iodosorb Powder should not be used in children under 12 years of age.
• Iodine may be absorbed systemically, especially when large wounds are treated.
• Patients with severely impaired renal function or a past history of thyroid disorder are more susceptible to alterations in thyroid metabolism with chronic Iodosorb Powder therapy.
• In endemic goitre, there have been isolated reports of hyperthyroidism associated with exogenous iodine.
• Iodine crosses the placental barrier. Clinical experience of use in pregnant women is limited. Iodosorb Powder should therefore not be used in pregnant women.
• Iodine is secreted into breast milk. Clinical experience of use in lactating women is limited. Iodosorb Powder should therefore not be used in lactating women.
• There is a potential risk of interaction with lithium resulting in an increased possibility of hyperthyroidism. Iodosorb Powder should not be used with mercurial antiseptics e.g. mercurochrome, thiomersal.
• A single application should not exceed 50g. The total amount of Iodosorb used in one week should not exceed 150g.
• The duration of treatment should not exceed 3 months in any single course of treatment.
• There is no experience in children, therefore Iodosorb Powder is not recommended.